Abstract
Since 2005, there has been a proliferation of molecularly targeted agents for the treatment of metastatic renal cell carcinoma. The necessity and timing of cytoreductive nephrectomy remains to be defined in the context of treatment with molecularly targeted agents. This chapter explores data on the safety and efficacy of molecularly targeted agents administered before cytoreductive nephrectomy, the unmet clinical needs, the key research questions, and the infrastructure required to definitively answer the questions of how to integrate cytoreductive surgery and systemic therapy in the treatment of patients with metastatic renal cell carcinoma.
Original language | English (US) |
---|---|
Title of host publication | Kidney Cancer |
Subtitle of host publication | Principles and Practice |
Publisher | Springer Berlin Heidelberg |
Pages | 241-248 |
Number of pages | 8 |
ISBN (Electronic) | 9783642218583 |
ISBN (Print) | 9783642218576 |
DOIs | |
State | Published - Jan 1 2012 |
ASJC Scopus subject areas
- General Medicine